New Generation Vaccines: Promising a Better Future for Your Furry Friend

Reimagined immunization, one joyful wag at a time

Vaccines have long served as silent guardians of animal health, protecting our furry friends from fatal illnesses like canine distemper, parvovirus and rabies. Yet, the world of immunology is ever evolving.

For decades, traditional DHPPi vaccines such as Canigen® and Nobivac® have served as the cornerstone of canine preventive medicine. These vaccines introduce killed or weakened forms of antigens (viruses and bacteria) to our immune system, which initiates a protective response by generating antibodies against them. Despite their corroborated effectiveness, their limitations include, in most cases, frequent boosters and in rare cases, adverse side effects, which include reverting back to pathogenicity. To transcend such constraints, innovation is of utmost importance, which has paved the way for what are now called novel vaccines, which are state-of-the-art inventions that combine precision, immunology, molecular biology, and biotechnology.

Revolutionizing Veterinary Vaccines with Genetic Technology

One of the most remarkable developments is the technology of DNA and mRNA vaccines. Instead of introducing a virus or bacterial fragment, these vaccines rely on delivering small strands of genetic material that instruct the body’s own cells to produce harmless proteins, like spike proteins, resembling the disease-causing agent. New doors have been opened for mRNA vaccines on the veterinary front, following their success during the COVID-19 pandemic. These vaccines are considered safer as they develop immunity without exposing the body to deadly pathogens. Researchers in the United States, Europe, and Japan are striving towards deploying similar approaches for enhancement in canine vaccinations, particularly targeting deadly diseases like rabies, distemper, and canine influenza. Early tests conducted by organizations such as the French National Veterinary School of Toulouse and the University of Pennsylvania School of Veterinary Medicine have revealed encouraging immune response by using these vaccines, with abundant antibody production in adult dogs and pups, with reduced side effects. These studies highlight the ability of mRNA vaccines to be swiftly modified for new canine virus strains and suggest the possibility of longer-lasting protection, eliminating the need for periodic booster shots.

Vector-Based Vaccines – Harnessing Viruses for Immunity

Similarly favourable are vector-based vaccines, which employ an immunological response by delivering genetic instructions into cells using a harmless modified virus (the vector), which causes the cells to generate a particular antigen. For instance, Purevax® Rabies (Boehringer Ingelheim, France) develops immunity in dogs, without using chemical adjuvants; instead, it harnesses canarypox virus as a carrier. Another illustration of a recombinant canarypox vector is Recombitek® (Merial, USA), which offers protection against multiple infections, such as distemper and parvovirus. These vaccines are currently being tested and are ideal for dogs that are elderly or immunocompromised.

Peptide-Based and Needle-

Free Vaccines – The Next Frontier in Veterinary Science

Another step towards manoeuvring safer vaccines is of subunit and peptide vaccines, which utilize purified or synthesized fragments of a pathogen, like a peptide, to stimulate immune response, rather than the whole organism, thus mimicking the pathogen’s surface to trigger immunity. This makes these vaccines safer compared to conventional vaccines. Although peptide vaccine prototypes, targeting tick-borne illnesses, are still under development in India and Spain, Leish-Tec®, a recombinant subunit vaccine developed in Brazil by Bio-Manguinhos, continues to shield thousands of dogs from canine leishmaniasis.

The world of vaccines is being redefined by the creation of needle-free vaccines. These needle-free vaccination methods range from using small patches that function like high-tech stickers to micro-jet sprays that inject medication into the skin and are studied across the United States, Germany, and Japan. They also tend to spark a stronger immune response, especially in puppies and needle-shy dogs.

Bridging the Gap –

The Future of Canine Vaccines

The creation of new vaccines goes beyond personal pet care and is part of a larger trend toward the One Health idea, linking the health of people, animals, and the environment. The likelihood of zoonotic illnesses infecting humans is reduced when the dog population is healthier. Adoption of mass vaccinations is currently being promoted by international initiatives run by the World Organization for Animal Health (WOAH), especially in Asia and Africa, where rabies is still widespread.

Demand for safer, more intelligent vaccination is increasing as pet owners become more conscious. From protracted testing periods, stringent international regulations, to expensive storage requirements, the vaccine research is not free from hindrances. The journey from labs to leashes is a tedious and expensive one. However, these divides are being closed by partnerships among scientists, academic institutions, and public health organizations. Vaccination is developing more quickly than ever before, from peptide and needle-free advances to DNA strands that train the body to fight illness. Every patch, spray, or injection stands as a testament to how far we’ve come in caring for those who trust us the most.

The concoction of science and love is the finest immune booster, as demonstrated by every joyful bark and wagging tail.

(Dr.Gauri Kohli – M.V. Sc Scholar, Department of Veterinary Epidemiology, COVSc & AH, DUVASU, Mathura; Dr. Barkha Sharma – Professor & Head, Department of Veterinary Epidemiology, COVSc & AH, DUVASU, Mathura)